School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.
Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1552-1559. doi: 10.1002/pds.4800. Epub 2019 May 27.
The United Kingdom's "Yellow Card Scheme" for reporting of adverse drug reactions (ADRs) has been operating for 50 years, but reporting rates by community pharmacists remain low. The aim of the study was therefore to investigate the views and experiences of ADR reporting by community pharmacists in Wales, with a particular focus on the potential barriers and facilitators to reporting.
Following ethics approval and piloting, a self-complete questionnaire was mailed to all registered community pharmacies in Wales, UK (n = 713). A follow-up mailing was sent to nonresponders after 2 weeks.
A response rate of 52% (n = 372) was achieved, of whom 57% had never submitted a yellow card. Key barriers to reporting were not seeing ADRs, difficulty identifying the causative drug, not being sure which ADRs to report, and lack of time. Key facilitators were being able to report through dispensary software and having clearer guidelines about what to report. Differences between those who had previously reported ADRs and those who had not suggested lack of confidence and uncertainty about what to report were more of a barrier for nonreporters. Conversely, reporters wanted feedback on reports, ability to keep reports on their dispensary records, and remuneration to aid them with reporting.
While the respondents generally expressed positive attitudes towards ADR reporting, a number of barriers and potential facilitators were nevertheless identified. Clearer support and guidance for reporting, such as through a "champions" scheme similar to that run in Welsh hospitals, may help current nonreporters to engage.
英国的药品不良反应(ADR)报告“黄卡计划”已经运行了 50 年,但社区药剂师的报告率仍然很低。因此,本研究旨在调查威尔士社区药剂师对 ADR 报告的看法和经验,特别关注报告的潜在障碍和促进因素。
在获得伦理批准和试点后,向英国威尔士所有注册的社区药房(n=713)邮寄了一份自我完成的问卷。在两周后,对未回复者进行了跟进邮寄。
实现了 52%(n=372)的回复率,其中 57%的人从未提交过黄卡。报告的主要障碍是未看到 ADR、难以识别致病药物、不确定要报告哪些 ADR 以及缺乏时间。主要的促进因素是能够通过配药软件报告,以及对要报告的内容有更清晰的指南。有过 ADR 报告经历和没有过报告经历的人之间的差异表明,缺乏信心和对报告内容的不确定性对于非报告者来说是更大的障碍。相反,报告者希望对报告进行反馈、能够在其配药记录上保留报告以及获得报酬以帮助他们进行报告。
尽管受访者普遍对 ADR 报告持积极态度,但仍确定了一些障碍和潜在的促进因素。更清晰的报告支持和指导,例如通过类似于威尔士医院运行的“冠军”计划,可能有助于目前的非报告者参与。